Comment
Delamanid: does it have a role in tuberculosis treatment?

https://doi.org/10.1016/S2213-2600(18)30455-7Get rights and content

First page preview

First page preview
Click to open first page preview

References (11)

  • F von Groote-Bidlingmaier et al.

    Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

    Lancet Respir Med

    (2019)
  • WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrugresistant Tuberculosis. WHO/HTM/TB/2017.20

  • E Pontali et al.

    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline

    Eur Respir J

    (2017)
  • E Pontali et al.

    Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence

    Eur Respir J

    (2017)
  • AH Diacon et al.

    Multidrug-resistant tuberculosis and culture conversion with bedaquiline

    N Engl J Med

    (2014)
There are more references available in the full text version of this article.

Cited by (4)

View full text